Jean Jeudy

Cardiac tumours: an update

Cardiologists evaluate cardiac masses after clinical symptoms lead to a positive imaging study, or because of an incidental mass found at imaging, usually echocardiography. Cardiac masses range from non-neoplastic lesions to high grade malignancies (box 1) and occur over a wide range of ages (table 1). Ninety per cent of primary cardiac tumours are either myxomas, which are cured by resection, or sarcomas, which have a dismal prognosis regardless of treatment (table 1).1–5 View this table: Table 1 Incidence of primary cardiac tumours* by mean age at presentation† Although the vast majority of heart tumour patients are readily referred to the surgeon (and eventually oncologist in the case of sarcoma), the rare patient with a heart tumour causes great interest among clinical cardiologists. Cardiac myxomas have a wide range of clinical presentations that may mimic a variety of non-neoplastic conditions. Most cardiac masses are not amenable to percutaneous biopsy; therefore definitive diagnosis often awaits surgical excision and allows for a time of suspense during which differential diagnoses are discussed. The 10% of heart tumours that are not myxoma or sarcoma comprise a quite varied group of lesions. Cardiac masses that are discovered by imaging can be considered in three groups: paediatric tumours, which are mostly hamartomas and are associated in many cases with genetic syndromes; benign tumours, both non-neoplastic masses and benign neoplasms, which are generally cured by surgery; and malignancies, which are mostly primary cardiac sarcomas, but which include lymphoma and metastases (with known or occult primary) (box 1). In this article, tumours will be presented based on usual site in the heart, as differential diagnosis varies greatly by site (table 2). Primary tumours may arise in adults most frequently from the endocardium, followed by the cardiac muscle, and, most infrequently, the pericardium. Interestingly, the rate of metastatic lesions is the reverse; the pericardium is by far the most common …

MRI-Guided ventricular tachycardia ablation: integration of late gadolinium-enhanced 3D scar in patients with implantable cardioverter-defibrillators.

Background— Substrate-guided ablation of ventricular tachycardia (VT) in patients with implanted cardioverter-defibrillators (ICDs) relies on voltage mapping to define the scar and border zone. An integrated 3D scar reconstruction from late gadolinium enhancement (LGE) MRI could facilitate VT ablations. Methods and Results— Twenty-two patients with ICD underwent contrast-enhanced cardiac MRI with a specific absorption rate of 0.05). ICD imaging artifacts were most prominent in the anterior wall and allowed full and partial assessment of LGE in 9±4 and 12±3 of 17 segments, respectively. In 14 patients with LGE, a 3D scar model was reconstructed and successfully registered with the clinical mapping system (accuracy, 3.9±1.8 mm). Using receiver operating characteristic curves, bipolar and unipolar voltages of 1.49 and 4.46 mV correlated best with endocardial MRI scar. Scar visualization allowed the elimination of falsely low voltage recordings (suboptimal catheter contact) in 4.1±1.9% of 2 mm resulted in >1.5-mV voltage recordings despite up to 63% transmural midmyocardial scar successfully ablated with MRI guidance. All successful ablation sites demonstrated LGE (transmurality, 68±26%) and were located within 10 mm of transition zones to 0% to 25% scar in 71%. Conclusions— Contrast-enhanced cardiac MRI can be safely performed in selected patients with ICDs and allows the integration of detailed 3D scar maps into clinical mapping systems, providing supplementary anatomic guidance to facilitate substrate-guided VT ablations.Background— Substrate-guided ablation of ventricular tachycardia (VT) in patients with implanted cardioverter-defibrillators (ICDs) relies on voltage mapping to define the scar and border zone. An integrated 3D scar reconstruction from late gadolinium enhancement (LGE) MRI could facilitate VT ablations. Methods and Results— Twenty-two patients with ICD underwent contrast-enhanced cardiac MRI with a specific absorption rate of <2.0 W/kg before VT ablation. Device interrogation demonstrated unchanged ICD parameters immediately before, after, or at 68±21 days follow-up (P>0.05). ICD imaging artifacts were most prominent in the anterior wall and allowed full and partial assessment of LGE in 9±4 and 12±3 of 17 segments, respectively. In 14 patients with LGE, a 3D scar model was reconstructed and successfully registered with the clinical mapping system (accuracy, 3.9±1.8 mm). Using receiver operating characteristic curves, bipolar and unipolar voltages of 1.49 and 4.46 mV correlated best with endocardial MRI scar. Scar visualization allowed the elimination of falsely low voltage recordings (suboptimal catheter contact) in 4.1±1.9% of <1.5-mV mapping points. Display of scar border zone allowed identification of excellent pace mapping sites, with only limited voltage mapping in 64% of patients. Viable endocardium of >2 mm resulted in >1.5-mV voltage recordings despite up to 63% transmural midmyocardial scar successfully ablated with MRI guidance. All successful ablation sites demonstrated LGE (transmurality, 68±26%) and were located within 10 mm of transition zones to 0% to 25% scar in 71%. Conclusions— Contrast-enhanced cardiac MRI can be safely performed in selected patients with ICDs and allows the integration of detailed 3D scar maps into clinical mapping systems, providing supplementary anatomic guidance to facilitate substrate-guided VT ablations.

Cardiac CT angiography after coronary bypass surgery: prevalence of incidental findings.

OBJECTIVE Cardiac CT angiography (CTA) is commonly performed after coronary artery bypass grafting surgery (CABG) to assess graft patency, but the images also include parts of the lungs, abdomen, and mediastinum. The purpose of our study was to retrospectively assess the prevalence of unsuspected disease identified on cardiac CTA examinations after CABG and to determine their potential clinical significance. MATERIALS AND METHODS CTA was performed postoperatively in 259 patients (mean, 5.2 days), and 40 patients underwent a follow-up CT scan (mean, 12.7 months). Cardiac CTA was acquired using a 16-MDCT scanner with ECG-gating and bolus timing with a small field of view centered on the heart. Two thoracic radiologists assessed each examination in consensus. The prevalence of graft disease and incidental findings (cardiac and noncardiac) was established. The electronic medical record was reviewed. A finding was judged potentially significant if a therapeutic intervention or radiologic follow-up was deemed advisable on the basis of the cardiac CTA. Bypass graft occlusions were analyzed separately. RESULTS In the immediate postoperative period, 51 patients (19.7%) had at least one unsuspected, potentially significant finding. Twenty-four patients (9.3%) had a cardiac finding such as a ventricular pseudoaneurysm, ventricular perfusion deficit, or intracardiac thrombus, and 34 patients (13.1%) had a noncardiac finding including pulmonary embolism, lung cancer, or pneumonia. At least one bypass graft was occluded in 17 patients (6.6%) in the immediate postoperative period. In the later postoperative period, seven patients (17.5%) had a potentially significant unsuspected finding. Four patients (10.0%) had at least one graft occlusion. CONCLUSION Cardiac CTA after CABG revealed a high prevalence of unsuspected cardiac and noncardiac findings with potential clinical significance. Interpreters of these studies should be familiar with the spectrum of these abnormalities.

Three-dimensional contrast-enhanced multidetector CT for anatomic, dynamic, and perfusion characterization of abnormal myocardium to guide ventricular tachycardia ablations.

Background—Advances in contrast-enhanced multidetector CT enable detailed characterization of the left ventricular myocardium. Myocardial scar and border zone (BZ), as the target of ventricular tachycardia ablations, displays abnormal anatomic, dynamic, and perfusion characteristics during first-pass CT. This study assessed how contrast-enhanced CT can predict voltage-defined scar and BZ and integrate its scar reconstructions into clinical mapping systems to guide ventricular tachycardia ablations. Methods and Results—Eleven patients with ischemic cardiomyopathy underwent contrast-enhanced CT before ventricular tachycardia ablation. Segmental anatomic (end-systolic and end-diastolic wall thickness), dynamic (wall thickening, wall motion), and perfusion (hypoenhancement) characteristics were evaluated. Receiver operating characteristic curves assessed the ability of CT to determine voltage-defined scar and BZ segments. Three-dimensional epi- and endocardial surfaces and scar borders were reconstructed, coregistered, and compared to voltages using a 17-segment model. Abnormal anatomic, dynamic, and perfusion data correlated well with abnormal (<1.5 mV) endocardial voltages (r=0.77). Three-dimensional reconstruction integrated into the clinical mapping system (registration accuracy, 3.31±0.52 mm) allowed prediction of homogenous abnormal voltage (<1.5 mV) in 81.7% of analyzed segments and correctly displayed transmural extent and intramural scar location. CT hypoperfusion correlated best with scar and BZ areas and encompassed curative ablations in 82% cases. Conclusions—Anatomic, dynamic, and perfusion imaging using contrast-enhanced CT allows characterization of left ventricular anatomy and 3D scar and BZ substrate. Integration of reconstructed 3D data sets into clinical mapping systems supplements information of voltage mapping and may enable new image approaches for substrate-guided ventricular tachycardia ablation.

CT Angiography of the Cardiac Valves: Normal, Diseased, and Postoperative Appearances

Although echocardiography remains the principal imaging technique for assessment of the cardiac valves, contrast material-enhanced electrocardiographically gated computed tomographic (CT) angiography is proving to be an increasingly valuable complementary modality in this setting. CT angiography allows excellent visualization of the morphologic features and function of the normal valves, as well as of a wide range of valve diseases, including congenital and acquired diseases, infectious endocarditis, and complications of valve replacement. The number, thickness, and opening and closing of the valve leaflets, as well as the presence of valve calcification, can be directly observed. CT angiography also permits simultaneous assessment of the valves and coronary arteries, which may prove valuable in presurgical planning. Unlike echocardiography and magnetic resonance imaging, however, CT angiography requires ionizing radiation and does not provide a direct measure of the valvular pressure gradient. Nevertheless, with further development of related imaging techniques, CT angiography can be expected to play an increasingly important role in the evaluation of the cardiac valves. Supplemental material available at http://radiographics.rsna.org/cgi/content/full/29/5/1393/DC1.

Three Dimensional Contrast Enhanced Multi-Detector CT for Anatomic, Dynamic and Perfusion Characterization of Abnormal Myocardium to Guide VT Ablations

Background—Advances in contrast-enhanced multidetector CT enable detailed characterization of the left ventricular myocardium. Myocardial scar and border zone (BZ), as the target of ventricular tachycardia ablations, displays abnormal anatomic, dynamic, and perfusion characteristics during first-pass CT. This study assessed how contrast-enhanced CT can predict voltage-defined scar and BZ and integrate its scar reconstructions into clinical mapping systems to guide ventricular tachycardia ablations. Methods and Results—Eleven patients with ischemic cardiomyopathy underwent contrast-enhanced CT before ventricular tachycardia ablation. Segmental anatomic (end-systolic and end-diastolic wall thickness), dynamic (wall thickening, wall motion), and perfusion (hypoenhancement) characteristics were evaluated. Receiver operating characteristic curves assessed the ability of CT to determine voltage-defined scar and BZ segments. Three-dimensional epi- and endocardial surfaces and scar borders were reconstructed, coregistered, and compared to voltages using a 17-segment model. Abnormal anatomic, dynamic, and perfusion data correlated well with abnormal (<1.5 mV) endocardial voltages (r=0.77). Three-dimensional reconstruction integrated into the clinical mapping system (registration accuracy, 3.31±0.52 mm) allowed prediction of homogenous abnormal voltage (<1.5 mV) in 81.7% of analyzed segments and correctly displayed transmural extent and intramural scar location. CT hypoperfusion correlated best with scar and BZ areas and encompassed curative ablations in 82% cases. Conclusions—Anatomic, dynamic, and perfusion imaging using contrast-enhanced CT allows characterization of left ventricular anatomy and 3D scar and BZ substrate. Integration of reconstructed 3D data sets into clinical mapping systems supplements information of voltage mapping and may enable new image approaches for substrate-guided ventricular tachycardia ablation.

Use of a computer-aided detection system to detect missed lung cancer at chest radiography.

PURPOSE To study the ability of a computer-aided detection (CAD) system to detect lung cancer overlooked at initial interpretation by the radiologist. MATERIALS AND METHODS Institutional review board approval was given for this study. Patient consent was not required; a HIPAA waiver was granted because of the retrospective nature of the data collection. In patients with lung cancer diagnosed from 1995 to 2006 at two institutions, each chest radiograph obtained prior to tumor discovery was evaluated by two radiologists for an overlooked lesion. The size and location of the nodules were documented and graded for subtlety (grades 1-4, 1 = very subtle). Each radiograph with a missed lesion was analyzed by a commercial CAD system, as was the follow-up image at diagnosis. An age- and sex-matched control group was used to assess CAD false-positive rates. RESULTS Missed lung cancer was found in 89 patients (age range, 51-86 years; mean age, 65 years; 80 men, nine women) on 114 radiographs. Lesion size ranged from 0.4 to 5.5 cm (mean, 1.8 cm). Lesions were most commonly peripheral (n = 63, 71%) and in upper lobes (n = 67, 75%). Lesion subtlety score was 1, 2, 3, or 4 on 43, 49, 17, and five radiographs, respectively. CAD identified 53 (47%) and 46 (52%) undetected lesions on a per-image and per-patient basis, respectively. The average size of lesions detected with CAD was 1.73 cm compared with 1.85 cm for lesions that were undetected (P = .47). A significant difference (P = .017) was found in the average subtlety score between detected lesions (score, 2.06) and undetected lesions (score, 1.68). An average of 3.9 false-positive results occurred per radiograph; an average of 2.4 false-positive results occurred per radiograph for the control group. CONCLUSION CAD has the potential to detect approximately half of the lesions overlooked by human readers at chest radiography.

Centrilobular emphysema combined with pulmonary fibrosis results in improved survival

BackgroundWe hypothesized that, in patients with pulmonary fibrosis combined with emphysema, clinical characteristics and outcomes may differ from patients with pulmonary fibrosis without emphysema. We identified 102 patients who met established criteria for pulmonary fibrosis. The amount of emphysema (numerical score) and type of emphysema (centrilobular, paraseptal, or mixed) were characterized in each patient. Clinical characteristics, pulmonary function tests and patient survival were analysed.ResultsBased on the numerical emphysema score, patients were classified into those having no emphysema (n = 48), trivial emphysema (n = 26) or advanced emphysema (n = 28). Patients with advanced emphysema had a significantly higher amount of smoking in pack/years than patients with no emphysema or trivial emphysema (P < 0.0001). Median survival [1st, 3rd quartiles] of patients with advanced emphysema was 63 [36, 82] months compared to 29 [18, 49] months in patients without emphysema and 32 [19, 48] months in patients with trivial emphysema (P < 0.001). Median forced vital capacity (FVC) and total lung capacity (TLC) were higher in the advanced emphysema group compared to patients with no emphysema (P < 0.01 and P < 0.001, respectively), whereas median DLCO did not differ among groups and was overall low. Within the advanced emphysema group (n = 28), further characterization of the type of emphysema was performed and, within these subgroups of patients, survival was 75 [58, 85] months for patients with centrilobular emphysema, 75 [48, 85] months for patients with mixed centrilobular/paraseptal emphysema, and 24 [22, 35] months for patients with paraseptal emphysema (P < 0.01). Patients with advanced paraseptal emphysema had similar survival times to patients without emphysema.ConclusionsPatients with pulmonary fibrosis combined with advanced centrilobular or mixed emphysema have an improved survival compared with patients with pulmonary fibrosis without emphysema, with trivial emphysema or with advanced paraseptal emphysema.

Acute lung infections in normal and immunocompromised hosts

Pulmonary infections are among the most common causes of morbidity and mortality worldwide, and contribute substantially to annual medical expenditures in the United States. Despite the availability of antimicrobial agents, pneumonia constitutes the sixth most common cause of death and the number one cause of death from infection. Pneumonia can be particularly life-threatening in the elderly, in individuals who have pre-existing heart and lung conditions, in patients who have suppressed or weakened immunity, and in pregnant women. This article discusses some of the important causes of acute lung infections in normal and immunocompromised hosts. Because there often is considerable overlap, infections are categorized by the host immune status that is most likely to be associated with a particular pathogen.

From the Radiologic Pathology Archives: Cardiac Lymphoma: Radiologic-Pathologic Correlation

Lymphoma of the heart and pericardium is usually present as one aspect of disseminated disease and rarely occurs as a primary malignancy. It accounts for 1.3% of primary cardiac tumors and 0.5% of extranodal lymphomas. Cardiac lymphomas are most commonly diffuse large cell lymphomas and frequently manifest as an ill-defined, infiltrative mass. Atrial location is typical; the right atrium is most often affected. Pericardial thickening or effusion is often a common early feature of disease. Infiltration of atrial or ventricular walls with extension along epicardial surfaces is also a notable feature. At computed tomography, the attenuation of cardiac lymphoma may be similar to or lower than that of normal myocardium. At magnetic resonance imaging, it has variable signal intensity and contrast enhancement. Clinical manifestations may include pericardial effusion, cardiac arrhythmias, and a variety of nonspecific electrocardiographic abnormalities, notably first- to third-degree atrioventricular block. Treatment most commonly includes anthracycline-based chemotherapy and anti-CD20 treatment. Chemotherapy has been used alone or combined with radiation therapy. Palliative surgery has been performed, mainly for tumor debulking. The prognosis for patients with either primary or secondary lymphomatous heart involvement is usually poor; late diagnosis is one of the major factors affecting outcome.